Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Variant-Adapted BNT162b2 Vaccines
NCT05004181Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of multivalent BNT162b2, tozinameran, BNT162b2 (B.1.1.7), BNT162b2 (B.1.1.529.1) in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Aug 2021; status: completed.
02
Drugs
multivalent BNT162b2tozinameranBNT162b2 (B.1.1.7)BNT162b2 (B.1.1.529.1)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05004181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004181.